ARMP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 15:41):

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide...

Stats
Today's Volume	4 846.00
Average Volume	15 966.00
Market Cap	90.37M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.280 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.310
ATR14	$0.0840 (3.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-14	Patti Joseph M	Buy	54 343	Stock Options (Right to Buy)
2024-03-14	Patti Joseph M	Buy	39 666	Stock Options (Right to Buy)
2024-03-14	Kramer Robin	Buy	54 343	Stock Options (Right to Buy)
2024-03-14	Kramer Robin	Buy	39 666	Stock Options (Right to Buy)
2024-03-14	Peterson Todd C.	Buy	54 343	Stock Options (Right to Buy)

INSIDER POWER
98.32
Last 92 transactions
Buy: 43 961 909 \| Sell: 1 182 185

Armata Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Armata Pharmaceuticals Financials

Annual	2023
Revenue:	$4.53M
Gross Profit:	$3.56M (78.54 %)
EPS:	$-1.910

Q4	2023
Revenue:	$1.53M
Gross Profit:	$1.24M (80.82 %)
EPS:	$-0.550

Q3	2023
Revenue:	$1.23M
Gross Profit:	$1.00M (81.96 %)
EPS:	$-0.860

Q2	2023
Revenue:	$980 000
Gross Profit:	$780 000 (79.59 %)
EPS:	$-0.0983

Financial Reports:

No articles found.

Armata Pharmaceuticals

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.